Latest news with #AlphaGenome
Yahoo
a day ago
- Business
- Yahoo
Alphabet Google's (GOOGL) DeepMind Unveils AlphaGenome to Revolutionize DNA Research
Alphabet Inc. (NASDAQ:GOOGL) is one of the . On June 25, Google's DeepMind announced the launch of AlphaGenome: an AI model that helps scientists better understand DNA, the hereditary material in all organisms. The new artificial intelligence tool by Google is designed to predict how genetic variations in human DNA impact biological processes that regulate genes. This AI model is capable of analyzing up to 1 million DNA base pairs and predicting thousands of molecular properties related to regulatory activity. It can also assess the effects of genetic variants by comparing predictions between mutated and unmutated sequences. The company is making AlphaGenome available in preview via their AlphaGenome API for non-commercial research, and also plans to release the model in the future. The predictive capabilities offered by AlphaGenome will help more accurately predict genetic disruptions, guide the design of synthetic DNA with specific regulatory function, and also accelerate our understanding of the genome. Photo by Kai Wenzel on Unsplash 'AlphaGenome will be a powerful tool for the field. Determining the relevance of different non-coding variants can be extremely challenging, particularly to do at scale. This tool will provide a crucial piece of the puzzle, allowing us to make better connections to understand diseases like cancer.' -Professor Marc Mansour, University College London Alphabet Inc. (NASDAQ:GOOG) is an American multinational technology conglomerate holding company wholly owning the internet giant Google, amongst other businesses. While we acknowledge the potential of GOOG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 AI Stocks in the Spotlight and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
India Today
2 days ago
- Science
- India Today
Google DeepMind unveils AlphaGenome, AI to decode how DNA changes impact human health
Recently, when Demis Hassabis, the CEO of Google DeepMind won Nobel Prize he did not win it for physics. Instead, he won in for chemistry, specifically the kind of chemistry that goes into our bodies inside our genes and DNA. Now, DeepMind has introduced a new artificial intelligence model AlphaGenome. This is a new AI model that is specifically tuned to accurately predict how individual mutations in human DNA affect their functions. advertisementIn other words, the AI will help scientists and doctors better understanding of genome functions. This advanced AI model, developed by DeepMind, is said to bring a major leap in the research around genome. The human genome is a complete set of genetic instructions. Think of it as a comprehensive instruction manual which has the data to build and operate a living thing. Its genetic material primarily consists of DNA. Genomes can influence everything from physical traits of a human being to possible risks of diseases like cancer. A small change in our DNA can bring in major effects to our health. However right now understanding of the genes and how these changes work at a molecular level is one of the biggest challenges for biologists. DeepMinds AlphaGenome AI aims to help researchers solve these answers by providing deeper insights into genome mechanisms, especially in the parts that don't directly code for proteins but still play critical roles in regulating our AlphaGenome worksadvertisement DeepMind explains that at its core, AlphaGenome is particularly unique is its ability to evaluate both common and rare genetic variants, which are the small changes in our DNA that make each person unique. This, according to the company, is made possible by major technical advances that let the model analyze extremely long DNA sequences — up to 1 million base pairs — and generate highly detailed predictions. More importantly, the AI model can do this across many different cell types and biological processes, all within a single reveals that the new AlphaGenome was trained using extensive public datasets from large consortia such as ENCODE, GTEx, 4D Nucleome, and FANTOM5 which meticulously measured these properties across numerous human and mouse cell now, researchers often relied on multiple tools to study how genetic mutations affect different aspects of gene regulation. However, according to DeepMind AlphaGenome changes this process. It combines several capabilities into one model, reducing the need for fragmented approaches and enabling faster, more comprehensive AlphaGenome builds upon Google DeepMind's earlier genomics model, Enformer, and complements AlphaMissense, which specializes in analyzing variants within the 2 per cent of the genome that codes for proteins. The company highlights that AlphaGenome offers a vital new perspective for interpreting the vast remaining 98 percent—the non-coding regions—which are essential for orchestrating gene activity and contain many variants linked to company highlights that researchers are already using AlphaGenome to explore how certain genetic mutations may lead to cancer. In one test, it accurately predicted how a mutation linked to leukaemia could activate a harmful gene, confirming previous experimental availability AlphaGenome is currently available through an API for non-commercial, research-focused use. While it is not approved for clinical diagnosis, Google says the AI tool can help scientists identify which mutations are most likely to cause disease. However the company notes that the model is still evolving, and future versions may cover more species, cell types, or biological processes. - Ends
Yahoo
2 days ago
- Science
- Yahoo
AlphaGenome: New Google AI reads DNA mutations, predicts molecular consequences
In a big leap for genomics, Google on Wednesday unveiled a powerful AI model that predicts how single DNA mutations affect the complex machinery regulating gene activity. Named AlphaGenome, the tool covers both coding and non-coding regions of the genome, offering a unified view of variant effects like never before. It brings base-resolution insight to long-range genomic analysis, decoding the impact of mutations with speed, scale, and unprecedented depth. The model processes up to 1 million base pairs in a single pass and predicts thousands of molecular properties, including gene expression, splicing patterns, protein-binding sites, and chromatin accessibility across diverse cell types. It's the first time such a wide range of regulatory features can be modeled jointly using one AI system. AlphaGenome's architecture first uses convolutional layers to spot short patterns in the DNA sequence, then applies transformers to share information across the entire stretch of genetic code. A final set of layers converts these learned patterns into predictions across various genomic features. During training, all computations for a single sequence are distributed across multiple interconnected Tensor Processing Units (TPUs), enabling efficient large-scale processing. A single model was trained in just four hours, using half the compute budget required for its predecessor, Enformer. Built as a successor to Enformer and complementing AlphaMissense, AlphaGenome is the only model that can jointly predict all evaluated molecular modalities, outperforming or matching specialized models in 24 of 26 benchmark tests. It was trained on massive public datasets including ENCODE, GTEx, 4D Nucleome, and FANTOM5. Unlike earlier models that traded sequence length for resolution, AlphaGenome handles both with precision. It captures long-range genomic context and offers base-level predictions, unlocking insights across disease biology, rare variant research, synthetic DNA design, and more. One standout feature of the new model is its variant scoring system, which efficiently contrasts mutated and unmutated DNA to assess impact across modalities. It also features splice-junction modeling, a first-of-its-kind approach to predicting RNA splicing disruptions tied to diseases like cystic fibrosis and spinal muscular atrophy. In synthetic biology, AlphaGenome could help design regulatory sequences that activate genes selectively, for instance, in nerve cells but not muscle cells. The model could also prove useful in studying rare variants with large biological effects, such as those responsible for Mendelian disorders. In a test case, AlphaGenome accurately predicted how a leukemia-linked mutation introduces a MYB DNA binding motif that activates the TAL1 gene, mirroring known mechanisms in T-cell acute lymphoblastic leukemia and showcasing its power to connect non-coding variants to disease genes. While AlphaGenome marks a major advance, it's not designed or validated for personal genome interpretation or clinical use. It also faces challenges in modeling very distant regulatory interactions — especially those over 100,000 DNA letters away — and in fully capturing cell- and tissue-specific patterns. Still, researchers say it lays a strong foundation for future expansion, with potential to be adapted for additional species, modalities, and lab-specific datasets. AlphaGenome is now available in preview for non-commercial use via the AlphaGenome API. Google is inviting researchers worldwide to explore use cases, ask questions, and share feedback. The AI-powered tool's predictions are intended strictly for research purposes. 'We hope AlphaGenome will help deepen our understanding of the complex cellular processes encoded in DNA,' Google said, 'and drive new discoveries in genomics and healthcare.'
